Reported
Lowest–highest estimate
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Price:
43.04
USD
-2.12%
Market Closed
Market Cap:
$2.5B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
|
US |
|
Y
|
YIT Oyj
DUS:YIT
|
FI |
|
Fideicomiso Irrevocable de Emision de Certificados Bursatiles Fiduciarios Inmobiliarios Administracion y Pago Numero CIB/572
BMV:STORAGE18
|
MX |
|
Tamboli Capital Ltd
BSE:533170
|
IN |
|
Sun Life Financial Inc
TSX:SLF
|
CA |
|
Cortelco Systems Puerto Rico Inc
OTC:CPROF
|
PR |
|
Cresud SACIF y A
NASDAQ:CRESY
|
AR |
|
Ypsomed Holding AG
OTC:YPHDF
|
CH |
|
M
|
MasTec Inc
F:MY8
|
US |
Wall St Price Targets
SUPN Price Forecast
Based on 7 analysts
Based on 7 analysts
+54% Upside
from
$43.04
today
Supernus Pharmaceuticals Inc (SUPN)’s 12-month stock price forecast through September 2027 has a consensus target of $66.3, implying 54% upside. The forecast is based on price targets from 7 Wall Street analysts.
SUPN Analyst Rating
Based on 5 analysts
Based on 5 analysts
Analysts rate SUPN Buy, with 2 of 5 recommending Buy or Strong buy.
Supernus Pharmaceuticals Inc Competitors:
Price Targets
Price Targets
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is SUPN's stock price target?
Price Target
66.3
USD
66.3
USD
According to Wall Street analysts, the average 1-year price target for SUPN is 66.3 USD with a low forecast of 55.55 USD and a high forecast of 70.35 USD.
What is the Revenue forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
8%
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 61%. The projected CAGR for the next 8 years is 8%.
What is the Gross Profit forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
7%
7%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 59%. The projected CAGR for the next 8 years is 7%.
What is the Operating Income forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
61%
61%
The compound annual growth rate for Operating Income over the next 8 years is 61%.